Evommune Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Evommune Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Palo Alto
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
EVMN
Primary stock exchange
NYSE

Identifiers

SEC CIK
0002044725
EIN
85-0742575

Board of directors

Follow this board

Chief executives

Luis C. Pena · President & CEO
Dates unknown

Director election results

Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

6 of this board's directors also sit on 28 other boards.

Network of Evommune Inc.'s board connections Acrivon Therapeutics Inc. Acrivon Therapeutics I... Mineralys Therapeutics Inc. Mineralys Therapeutics... Werewolf Therapeutics Inc. Werewolf Therapeutics... ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... LENZ Therapeutics Inc. LENZ Therapeutics Inc. Nkarta Inc. Nkarta Inc. Parabilis Medicines Inc. Parabilis Medicines In... Derek DiRocco Derek DiRocco Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Evommune Inc.
Shared director Other board Same sector +12 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$70,163,610
7 purchases by 6 insiders
Sold, last 12 months
$2,279,118
9 sales by 6 insiders
Date Insider Transaction Shares Price Value
Jul 8, 2026 Carver Kyle Officer (Chief Financial Officer) Open-market purchase +1,000 $13.26 $13,260
Jul 7, 2026 Arthur S. Kirsch Director Open-market purchase +10,000 $13.30 $133,000
Jun 22, 2026 Drew Janice Suzann Officer (Chief of Dev. Operations) Option exercise +3,839 $3.84 $14,742
Jun 22, 2026 Patel Jeegar Pravinkumar Officer (Chief Scientific Officer) Option exercise +1,488 $3.84 $5,714
Jun 22, 2026 Luis C. Pena Director, Officer (President & CEO) Open-market sale −7,438 $22.71 $168,917
Jun 22, 2026 Drew Janice Suzann Officer (Chief of Dev. Operations) Option exercise +16,161 $2.99 $48,321
Jun 22, 2026 Patel Jeegar Pravinkumar Officer (Chief Scientific Officer) Open-market sale −1,488 $22.50 $33,480
Jun 22, 2026 Drew Janice Suzann Officer (Chief of Dev. Operations) Open-market sale −20,000 $22.63 $452,600
Jun 2, 2026 David E. Cohen Director Open-market sale −5,456 $20.21 $110,266
Jun 2, 2026 David E. Cohen Director Open-market sale −600 $21.38 $12,828
Jun 1, 2026 Patel Jeegar Pravinkumar Officer (Chief Scientific Officer) Option exercise +13,512 $3.84 $51,886
Jun 1, 2026 Luis C. Pena Director, Officer (President & CEO) Open-market sale −16,787 $22.74 $381,736
Jun 1, 2026 Patel Jeegar Pravinkumar Officer (Chief Scientific Officer) Open-market sale −16,687 $22.74 $379,462
May 28, 2026 Gregory S. Moss Officer (Chief Business & Legal Officer) Option exercise +14,223 $1.71 $24,321
May 28, 2026 Carver Kyle Officer (Chief Financial Officer) Option exercise +15,000 $2.99 $44,850

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.